Phase 3 study for people with Muscular Dystrophy

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Solid Biosciences Inc.
Registry number NCT07160634
Started 22 October 2025 Today 16 October 2026 Estimated completion 1 January 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
The Children's Hospital of Westmead Sydney NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 7 Years to 11 Years
Sex Male participants only
Healthy volunteers Not accepted
Enrolment target 80

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Participant is ambulatory.

* Established clinical diagnosis of DMD and documented DMD gene mutation predictive of DMD phenotype.

* Negative for antibodies against adeno-associated virus serotype 9 (AAV9).

* On a stable daily oral regimen of at least 0.5 mg/kg/day prednisone or 0.75 milligrams per kilogram per day (mg/kg/day) deflazacort for at least 6 months prior to entering the study, allowing for weight-based dose modifications in accordance with clinical practice.

* Meet 10-meter walk/run time criteria.

* Meet time to rise from supine criteria.

* Participant has bodyweight ≤50 kg.

Exclusion Criteria:

* Current or prior treatment with an approved or investigational gene transfer drug or gene editing therapy.

* Exposure to vamorolone, givinostat, approved or investigational dystrophin- or disease-modifying drugs (such as eteplirsen, golodirsen, casimersen, viltolarsen, and ataluren), or another investigational drug for any indication within 6 months or 5 half-lives, whichever is longer, prior to enrollment.

* Established clinical diagnosis of DMD that is associated with any deletion variant or variant predicted not to express exons 1 to 11, exons 42 to 45, or exons 57 to 69, inclusive of the DMD gene as documented by a genetic report.

Other Inclusion/Exclusion criteria to be applied as per protocol.

Dates on the record

Started 22 October 2025
Estimated completion 1 January 2029
Registry last updated 28 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 28 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.